First-Ever Saliva-Based COVID and Influenza Combo Test to Screen for Coronavirus and Flu Infections
By HospiMedica International staff writers Posted on 26 Aug 2020 |
Illustration
Researchers are developing a potential coronavirus and influenza combo saliva-based test that would indicate if an individual has been infected by COVID-19, the flu, or neither, according to a report on NJ.com.
The research is being conducted at Rutgers University’s (New Brunswick, NJ, USA) RUCDR Infinite Biologics which had recently developed one of the first saliva-based coronavirus tests in the US. The researchers hope to receive approval for the coronavirus and influenza combo saliva test by the fall in time for the flu season, marking a crucial development as both the viruses share similar characteristics and symptoms.
The coronavirus and influenza combo saliva-based test has a preservation agent that mixes with the saliva and chemically stabilizes the ribonucleic acid extracted from the sample. The preservation agent also renders the virus inactive, making it safer to handle in the lab. Andrew Brooks, chief operating officer and director of technology development at RUCDR, told NJ.com that the lab was working on pooling strategies for a screening application, as well as studying how effective its current test would be in an asymptomatic population. The lab is hoping for continued developments, along with the coronavirus and flu combo test, before the end of 2020.
“There are other companies working on different panels, but this would be the first saliva-based COVID and influenza test,” Brooks said. “We’re gearing up, and we would like for it to be ready by the start of the flu season. Maybe even earlier. We’re not going to delay getting this.”
Related Links:
Rutgers University
The research is being conducted at Rutgers University’s (New Brunswick, NJ, USA) RUCDR Infinite Biologics which had recently developed one of the first saliva-based coronavirus tests in the US. The researchers hope to receive approval for the coronavirus and influenza combo saliva test by the fall in time for the flu season, marking a crucial development as both the viruses share similar characteristics and symptoms.
The coronavirus and influenza combo saliva-based test has a preservation agent that mixes with the saliva and chemically stabilizes the ribonucleic acid extracted from the sample. The preservation agent also renders the virus inactive, making it safer to handle in the lab. Andrew Brooks, chief operating officer and director of technology development at RUCDR, told NJ.com that the lab was working on pooling strategies for a screening application, as well as studying how effective its current test would be in an asymptomatic population. The lab is hoping for continued developments, along with the coronavirus and flu combo test, before the end of 2020.
“There are other companies working on different panels, but this would be the first saliva-based COVID and influenza test,” Brooks said. “We’re gearing up, and we would like for it to be ready by the start of the flu season. Maybe even earlier. We’re not going to delay getting this.”
Related Links:
Rutgers University
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans